References
- Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB. Efalizumab: Results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol. 2008; 158: 1107––16
- Genentech Announces Voluntary Withdrawal of Raptiva from the U.S. Market [press release on the Internet]. Genentech, Inc. South San Francisco, CA. April 8, 2009. Available from: http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=12047.
- Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol. 2006; 54: S171–81
- Gordon KB, Feldman SR, Koo JY, Menter A, Rolstad T, Krueger G. Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol. 2005; 141: 82–4
- Scheinfeld N. Efalizumab: A review of events reported during clinical trials and side effects. Expert Opin Drug Saf. 2006; 5: 197–209
- Cather JC, Cather JC, Menter A. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther. 2003; 3: 361–70
- Puig L, Roé E, García-navarro X, Corella F, Alomar A. Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice. Clin Exp Dermatol. 2008, Dec 2. Epub ahead of print
- Tsai TF, Liu MT, Liao YH, Licu D. Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study. J Eur Acad Dermatol Venereol. 2008; 22: 345–52
- Maskatia ZK, Koo J. Rebound of psoriasis after efalizumab discontinuation, despite being on high-dose cyclosporine. J Drugs Dermatol. 2007; 6: 941–4
- Golda N, Benham SM, Koo J. Rebound of psoriasis during treatment with efalizumab. J Drugs Dermatol. 2006; 5: 63–5
- Thielen AM, Barde C, Saurat JH. Infliximab- and methotrexate-resistant rebound of psoriasis after discontinuation of efalizumab (Raptiva). Br J Dermatol. 2006; 155: 846–7
- Menter A, Hamilton TK, Toth DP, Leung HM, Wetherill G, Hennessey B, et al. Transitioning patients from efalizumab to alternative psoriasis therapies: Findings from an open-label, multicenter, Phase IIIb study. Int J Dermatol. 2007; 46: 637–48
- Carey W, Rundle AC, Kwon P, Leonardi CL. Taper regimens in the management of patients discontinuing efalizumab therapy. Poster 29 presented at: 10th Annual International Psoriasis Symposium; June 10-13, 2004; Toronto, Ontario, Canada.
- Papp KA, Toth D, Rosoph L. Approaches to discontinuing efalizumab: Results of an open-label study comparing different transitioning therapies. Poster PDT9 presented at: 3rd European Academy of Dermatology and Venereology Spring Symposium; May 19-22, 2005; Sofia, Bulgaria.
- Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008; 58: 106–15